Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2025;31(Suppl):S182-S195. Published online November 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0837

View: 1906 Download: 162 Web of Science: 1 Crossref: 1

Prospect of emerging treatments for hepatitis B virus functional cure

Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2025;31(Suppl):S165-181. Published online November 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0855

View: 2276 Download: 364 Web of Science: 2 Crossref: 5

Editorial

Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Chih-Wen Wang, Ming-Lung Yu

Clin Mol Hepatol. 2025;31(2):606-609. Published online December 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.1078

View: 887 Download: 29 Crossref: 1

Reply to Correspondence

Reply to correspondence on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”

Antonio Bertoletti, Anthony T Tan

Clin Mol Hepatol. 2025;31(1):e113-e116. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0867

View: 1108 Download: 32

Correspondence

Correspondence to letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”

Gi-Ae Kim, Seung Won Choi, Young-Suk Lim

Clin Mol Hepatol. 2025;31(1):e108-e109. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0619

View: 1026 Download: 33

Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”

Shunda Du, Karin Wisskirchen, Ke Zhang, Ulrike Protzer

Clin Mol Hepatol. 2025;31(1):e44-e47. Published online October 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0781

View: 1164 Download: 42 Crossref: 1

Letter to the Editor

Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”

Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Yuanwang Qiu, Chao Wu, Rui Huang

Clin Mol Hepatol. 2025;31(1):e27-e30. Published online August 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0602

View: 1098 Download: 52 Crossref: 1

Reply to Correspondence

Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”

Cho-Rong Lee, Sung-Gyoo Park

Clin Mol Hepatol. 2024;30(4):1053-1054. Published online July 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0572

View: 1725 Download: 47 Web of Science: 1 Crossref: 1

Reply to correspondence on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”

Beom Kyung Kim

Clin Mol Hepatol. 2024;30(4):1044-1046. Published online July 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0584

View: 1266 Download: 26

Original Article

Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B

Gi-Ae Kim, Seung Won Choi, Seungbong Han, Young-Suk Lim

Clin Mol Hepatol. 2024;30(4):793-806. Published online July 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0252

View: 2932 Download: 211 Web of Science: 7 Crossref: 8

Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting

Xueshuai Wan, Karin Wisskirchen, Tao Jin, Lu Yang, Xiaorui Wang, Xiang’an Wu, Fang Liu, Yu Wu, Christy Ma, Yong Pang, Qi Li, Ke Zhang, Ulrike Protzer, Shunda Du

Clin Mol Hepatol. 2024;30(4):735-755. Published online May 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0058

View: 3935 Download: 345 Web of Science: 4 Crossref: 8

Editorial

Class II transactivator restricts viral replication, extending its effect to HBV: Editorial on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”

Cho-Rong Lee, Sung-Gyoo Park

Clin Mol Hepatol. 2024;30(4):724-727. Published online July 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.0465

View: 1704 Download: 74 Web of Science: 1 Crossref: 1

Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”

Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):705-708. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0372

View: 2214 Download: 70 Web of Science: 3 Crossref: 3

Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients”

Hae Lim Lee, Jeong Won Jang

Clin Mol Hepatol. 2024;30(4):692-694. Published online May 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0346

View: 1572 Download: 62

Original Article

Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction

Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim

Clin Mol Hepatol. 2024;30(3):539-560. Published online May 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0060 Correction in: Clin Mol Hepatol 2024;30(4):1060

View: 3985 Download: 276 Web of Science: 7 Crossref: 4

Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study

Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, Mi-Sook Kim, Jeayeon Park, Hyunjae Shin, Sung Won Chung, Hee Jin Cho, Min Kyung Park, Heejoon Jang, Yun Bin Lee, Su Jong Yu, Sang Hyub Lee, Yong Jin Jung, Yoon Jun Kim, Jung-Hwan Yoon

Clin Mol Hepatol. 2024;30(3):500-514. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0055

View: 3590 Download: 192 Web of Science: 3 Crossref: 4

Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients

Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L. Conery

Clin Mol Hepatol. 2024;30(3):375-387. Published online March 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0535

View: 3915 Download: 137 Web of Science: 1 Crossref: 1

Review

Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm

Yao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(4):869-890. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2022.0420

View: 4826 Download: 230 Web of Science: 14 Crossref: 20

Original Article

Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma

Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee

Clin Mol Hepatol. 2023;29(3):794-809. Published online May 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0057

View: 4800 Download: 177 Web of Science: 2 Crossref: 1

Letter to the Editor

Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”

Chia-Ming Chu, Yun-Fan Liaw

Clin Mol Hepatol. 2023;29(2):510-512. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0018

View: 3514 Download: 78 Web of Science: 1 Crossref: 1

Original Article

Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase

Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim

Clin Mol Hepatol. 2023;29(2):482-495. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0322

View: 4999 Download: 220 Web of Science: 19 Crossref: 21

Editorial

The imitator of immune-tolerant chronic hepatitis B: A killer in disguise

Moon Haeng Hur, Jeong-Hoon Lee

Clin Mol Hepatol. 2023;29(2):363-366. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0079

View: 3959 Download: 105 Web of Science: 2 Crossref: 2

Review

Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives

Shang-Chin Huang, Chun-Jen Liu

Clin Mol Hepatol. 2023;29(2):320-331. Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0422

View: 8699 Download: 480 Web of Science: 44 Crossref: 48

Editorial

New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?

Young-Suk Lim

Clin Mol Hepatol. 2023;29(1):118-119. Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0413

View: 4365 Download: 193 Web of Science: 6 Crossref: 4

Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers

Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2023;29(1):113-117. Published online October 31, 2022

DOI: https://doi.org/10.3350/cmh.2022.0333

View: 4050 Download: 118 Web of Science: 4 Crossref: 5

Original Article

Decreased vitamin D-binding protein level portends poor outcome in acute-on-chronic liver failure caused by hepatitis B virus

Daxian Wu, Qunfang Rao, Zhongyang Xie, Xiaoqing Zhu, Yuanmei Che, Jian Wu, Hainv Gao, Jingyu Zhang, Zhouhua Hou, Xiaoyu Cheng, Zeyu Sun

Clin Mol Hepatol. 2022;28(4):912-925. Published online July 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0121

View: 5653 Download: 157 Web of Science: 1 Crossref: 1

Review

RNA interference as a novel treatment strategy for chronic hepatitis B infection

Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2022;28(3):408-424. Published online February 17, 2022

DOI: https://doi.org/10.3350/cmh.2022.0012

View: 11090 Download: 692 Web of Science: 56 Crossref: 59

Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus

Sun Woong Kim, Jun Sik Yoon, Minjong Lee, Yuri Cho

Clin Mol Hepatol. 2022;28(1):17-30. Published online July 20, 2021

DOI: https://doi.org/10.3350/cmh.2021.0093

View: 12592 Download: 666 Web of Science: 44 Crossref: 45

Snapshot

History and future of hepatitis B virus control in South Korea

Do Young Kim

Clin Mol Hepatol. 2021;27(4):620-622. Published online September 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0277 Correction in: Clin Mol Hepatol 2022;28(4):939

View: 9019 Download: 166 Web of Science: 15 Crossref: 15

Original Article

Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea

Kyeong Deok Kim, Ji Eun Lee, Jong Man Kim, Okjoo Lee, Na Young Hwang, Jinsoo Rhu, Gyu-Seong Choi, Kyunga Kim, Jae-Won Joh

Clin Mol Hepatol. 2021;27(4):603-615. Published online September 8, 2021

DOI: https://doi.org/10.3350/cmh.2021.0137

View: 6368 Download: 150 Web of Science: 5 Crossref: 4

1 | 2 | 3 | 4 |

Viewed By 10564	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7443	MAFLD: How is it different from NAFLD?
Viewed By 5386	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4819	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 4809	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Cited By 338	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 305	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 210	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 104	Non-alcoholic fatty liver disease: Definition and subtypes

Search